Tuberculosis infection in children visiting friends and relatives in countries with high incidence of tuberculosis: A study protocol

Antoni Soriano-Arandes, Joan A Caylà, Alessandra Queiroga Gonçalves, Àngels Orcau, Antoni Noguera-Julian, Emma Padilla, Elisabet Solà-Segura, Neus Rius Gordillo, María Espiau, Mónica G García-Lerín, Maria Àngels Rifà-Pujol, Jordi Gómez I Prat, Esperança Macia-Rieradevall, Andrea Martin-Nalda, Maria Eril-Rius, José Santos Santiago, Lídia Busquets-Poblet, Raisa Morales Martínez, Tomàs Maria Pérez-Porcuna, Antoni Soriano-Arandes, Joan A Caylà, Alessandra Queiroga Gonçalves, Àngels Orcau, Antoni Noguera-Julian, Emma Padilla, Elisabet Solà-Segura, Neus Rius Gordillo, María Espiau, Mónica G García-Lerín, Maria Àngels Rifà-Pujol, Jordi Gómez I Prat, Esperança Macia-Rieradevall, Andrea Martin-Nalda, Maria Eril-Rius, José Santos Santiago, Lídia Busquets-Poblet, Raisa Morales Martínez, Tomàs Maria Pérez-Porcuna

Abstract

Introduction: Tuberculosis (TB) is a global infectious disease. In low-incidence countries, paediatric TB affects mostly immigrant children and children of immigrants. We hypothesize that these children are at risk of exposure to Mycobacterium tuberculosis when they travel to the country of origin of their parents to visit friends and relatives (VFR). In this study, we aim to estimate the incidence rate and risk factors associated to latent tuberculosis infection (LTBI) and TB in VFR children.

Methods and analysis: A prospective study will be carried out in collaboration with 21 primary health care centres (PCC) and 5 hospitals in Catalonia, Spain. The study participants are children under 15 years of age, either immigrant themselves or born to immigrant parents, who travel to countries with high incidence of TB (≥ 40 cases/100,000 inhabitants). A sample size of 492 children was calculated. Participants will be recruited before traveling, either during a visit to a travel clinic or to their PCC, where a questionnaire including sociodemographic, epidemiological and clinical data will be completed, and a tuberculin skin test (TST) will be performed and read after 48 to 72 hours; patients with a positive TST at baseline will be excluded. A visit will be scheduled eight to twelve-weeks after their return to perform a TST and a QuantiFERON-TB Gold Plus test. The incidence rate of LTBI will be estimated per individual/month and person/year per country visited, and also by age-group.

Ethics and dissemination: The study protocol was approved by the Clinical Research Ethics Committee of the Hospital Universitari Mútua Terrassa (code 02/16) and the Clinical Research Ethics Committee of the Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (code P16/094). Articles will be published in indexed scientific journals.

Trial registration: Clinical-Trials.gov: NCT04236765.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Countries considered in the study for having regions with an incidence of tuberculosis of 40 cases/100,000 inhabitants or greater.
Figure 2
Figure 2
Timeline of study visits and procedures.

References

    1. World Health Organization. Latent TB Infection: Updated and consolidated guidelines for programmatic management; 2018. Available in: Accessed February 22, 2020.
    1. World Health Organization. Global tuberculosis report 2019; 2019. Available in: Accessed May 21, 2020.
    1. Vanden Driessche K, Persson A, Marais BJ, et al. Immune vulnerability of infants to tuberculosis. Clin Dev Immunol 2013;2013:781320.
    1. Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis 2004;8:636–47..
    1. Thomas TA. Tuberculosis in Children. Pediatr Clin North Am 2017;64:893–909..
    1. Hoppe LE, Kettle R, Eisenhut M, et al. Tuberculosis--diagnosis, management, prevention, and control: summary of updated NICE guidance. BMJ 2016;352:h6747.
    1. Cruz AT, Starke JR, Lobato MN. Old and new approaches to diagnosing and treating latent tuberculosis in children in low-incidence countries. Curr Opin Pediatr 2014;26:106–13..
    1. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2018. Demographics; 2019. Available in: Accessed date May 10, 2020.
    1. European Centre for Disease Prevention and Control. Tuberculosis surveillance and monitoring in Europe, 2019; 2019. Available in: Accessed date April 5, 2020.
    1. Boggild AK, Geduld J, Libman M, et al. Spectrum of illness in migrants to Canada: sentinel surveillance through CanTravNet. J Travel Med 2019;26:tay117.
    1. Farah MG, Meyer HE, Selmer R, et al. Long-term risk of tuberculosis among immigrants in Norway. Int J Epidemiol 2005;34:1005–11..
    1. Cain KP, Benoit SR, Winston CA, et al. Tuberculosis among foreign-born persons in the United States. JAMA 2008;300:405–12..
    1. Schlagenhauf P, Weld L, Goorhuis A, et al. Travel-associated infection presenting in Europe (2008–12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation. Lancet Infect Dis 2015;15:55–64..
    1. Zuckerman JN. Recent developments: travel medicine. BMJ 2002;325:260–4..
    1. Monge-Maillo B, Norman FF, Pérez-Molina JA, et al. Travelers visiting friends and relatives (VFR) and imported infectious disease: travelers, immigrants or both? A comparative analysis. Travel Med Infect Dis 2014;12:88–94..
    1. Hendel-Paterson B, Swanson SJ. Pediatric travelers visiting friends and relatives (VFR) abroad: illnesses, barriers and pre-travel recommendations. Travel Med Infect Dis 2011;9:192–203..
    1. Elfrink F, van den Hoek A, Mensen ME, et al. Screening travellers to high-endemic countries for infection with Mycobacterium tuberculosis using interferon gamma release assay; a prospective study. BMC Infect Dis 2014;14:515.
    1. Denholm JT, Thevarajan I. Tuberculosis and the traveller: evaluating and reducing risk through travel consultation. J Travel Med 2016;23:taw008.
    1. Pareek M, Bond M, Shorey J, et al. Community-based evaluation of immigrant tuberculosis screening using interferon ( release assays and tuberculin skin testing: observational study and economic analysis. Thorax 2013;68:230–9..
    1. Agència de Salut Pública de Catalunya. Departament de Salut. Informe anual 2017. Situació epidemiològica i tendència de l’endèmia tuberculosa a Catalunya; 2019. Available in: . Accessed July 21, 2020.
    1. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81..
    1. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95:103208.
    1. Altet-Gómez N, Asensio O, Domínguez-Benítez JA, et al. Recomanacions per a la prevenció i el control de la tuberculosi pediàtrica a Catalunya; 2015. Available in: Accessed date January 10, 2020.
    1. Pai M, Riley LW, Colford JM., Jr Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761–76..
    1. Hunziker T, Berger C, Staubli G, et al. Profile of travel-associated illness in children, Zürich, Switzerland. J Travel Med 2012;19:158–62..
    1. Brown ML, Henderson SJ, Ferguson RW, et al. Revisiting tuberculosis risk in Peace Corps Volunteers, 2006-13. J Travel Med 2015;23:tav005.
    1. Kik SV, Mensen M, Beltman M, et al. Risk of travelling to the country of origin for tuberculosis among immigrants living in a low-incidence country. Int J Tuberc Lung Dis 2011;15:38–43..
    1. Lobato MN, Hopewell PC. Mycobacterium tuberculosis infection after travel to or contact with visitors from countries with a high prevalence of tuberculosis. Am J Respir Crit Care Med 1998;158:1871–5..
    1. Brophy J. Committee to Advise on Tropical Medicine, Travel (CATMAT). Summary of the Statement on International Travellers Who Intend to Visit Friends and Relatives. Can Commun Dis Rep 2015;41:89–99..
    1. Jagger A, Reiter-Karam S, Hamada Y, et al. National policies on the management of latent tuberculosis infection: review of 98 countries. Bull World Health Organ 2018;96:173–84F..
    1. Bertoncello C, Ferro A, Ferraresso A, et al. LTBI among migrants by Mediterranean Sea: assessing prevalence and its variations according with different thresholds and diagnostic tools. A 10-month on-field experience. J Travel Med 2018;25:tay020.
    1. Ritz N, Connell TG, Curtis N. To BCG or not to BCG? Preventing travel-associated tuberculosis in children. Vaccine 2008;26:5905–10..
    1. World Health Organization. WHO End TB Strategy; 2015. Available in: Accessed date December 27, 2019.
    1. Pai M, Denkinger CM, Kik SV, et al. Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clin Microbiol Rev 2014;27:3–20..
    1. Brassard P, Steensma C, Cadieux L, et al. Evaluation of a school-based tuberculosis-screening program and associate investigation targeting recently immigrated children in a low-burden country. Pediatrics 2006;117:e148–56..
    1. Perez-Porcuna TM, Pereira-da-Silva HD, Ascaso C, et al. Prevalence and diagnosis of latent tuberculosis infection in young children in the absence of a gold standard. PLoS One 2016;11:e0164181.
    1. Thomas TA, Mondal D, Noor Z, et al. Malnutrition and helminth infection affect performance of an interferon gamma-release assay. Pediatrics 2010;126:e1522–1529..

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren